Inhibrx FDA acceptance of BLA for ozekibart (INBRX-109) to treat chondrosarcom
Inhibrx Biosciences gets FDA acceptance of BLA for ozekibart (INBRX-109) to treat unresectable or metastatic conventional chondrosarcoma, PDUFA decision due April 14, 2027
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.